Suven Pharmaceutical Limited (SPL), a company specialized in providing pharmaceutical solutions to global life science companies, today announced its Un-audited Financial Results for the quarter and nine months ended 31st December 2019. The Un-audited Financial Results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13th February, 2020 at Hyderabad.
Post demerger of Suven Life Sciences Limited (SLSL), the resultant entity is SPL, continuing the operations of providing pharmaceuticals solutions to global life science companies. Post approval of Honorable National Company Law Tribunal (NCLT), the financials of SPL are separated 3rd quarter onwards from Suven Life Sciences. The below financial information relating to Suven Pharmaceutical Limited only.
Financial Highlights for the 3rd Quarter ended December' 2019 (QoQ):
- Income INR 1836 Mn vs 2784 Mn - down by 34.05%
- PAT INR 514 Mn vs 899 Mn - down by 42.85%
- EBIDTA INR 849 Mn vs 1310 Mn - down by 35.16%
The Board has declared an Interim Dividend of Re.2.50 per share (250% of face value of Rs. 1.00 each) and a one-time special dividend of Rs. 2.50 per share (250% of face value of Rs. 1.00 each) totaling to Rs. 5.00 per share (500% of face value of Rs. 1.00 each) post demerger of Suven's CRAMS business.